Author Archives: Iqra Mumal, MSc

Revlimid-based Therapies are Best Maintenance Option for Newly-diagnosed Multiple Myeloma Patients, Analysis Finds

Maintenance treatments containing the immunomodulatory therapy Revlimid (lenalidomide) are the best option for patients with multiple myeloma, according to a recent meta-analysis. The study, “Maintenance Treatment and Survival in Patients With Myeloma,” was published in the journal JAMA Oncology. The continuous therapy approach, which consists of administering a…

Stem Cell Transplants Better Than New Therapies at Delaying Myeloma Progression, Analysis Finds

In an era of new therapies with unprecedented efficacy, high-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) is still associated with better progression-free survival in newly-diagnosed multiple myeloma patients, researchers found. Autologous transplants use the patient’s own stem cells. A meta-analysis of randomized Phase 3 trials, titled…